Skip to main content
 

Stay Connected

Get information and updates from the Biosimilars Forum

Sign Up

Become a Partner

About the Biosimilars Forum

The Biosimilars Forum was incorporated in Washington, DC, as a nonprofit organization to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The Biosimilars Forum will provide evidence-based information to inform and support public policies that encourage awareness, access, and adoption of biosimilars.

The introduction of biosimilars in the United States may help expand access to high-quality treatment options for clinicians and patients as well as potentially reduce costs to families, caregivers, payers, and the entire health care system. Using state‐of‐the‐art technology, biosimilars are manufactured using the same with the same high-quality systems and processes as existing biological medicines.

The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios, including: Amgen, Boehringer Ingelheim, Coherus BioSciences, EMD Serono, Merck, Pfizer, Samsung Bioepis, Sandoz, and Teva.

The FDA approval of the first biosimilar in the United States and the ongoing development and production of other biosimilars serve as important milestones. The founding members and key stakeholders recognize there is a need for a sustained and unbiased biosimilars education and advocacy program in the U.S.

To this end, the development of an independent non-profit forum to raise awareness of biosimilars and serve as a credible resource for information is timely. The Biosimilars Forum will provide an opportunity for companies developing biosimilars for the U.S. to work together and with other key stakeholders on topics instrumental to biosimilars and patient care.

Learn more about biosimilars, the Forum, and how to get involved, visit BiosimilarsForum.org, or go to @USBiosimilars to follow related conversations and join the dialogue.